RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 250 points on Friday. Shares…
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday’s session after the company posted mixed first-quarter results.…
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday. Shares of Ambarella, Inc. (NASDAQ:AMBA)…
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Thursday. Shares of e.l.f.…
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Wednesday.…
Gold Down Over 1%; AC Immune Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 50…
Why Is Small-Cap Alzheimer’s-Focused AC Immune Stock Trading Higher On Monday?
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression.
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of Akoustis Technologies, Inc. (NASDAQ:AKTS) fell sharply in today’s session following weak quarterly results. Akoustis Technologies posted…
Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 0.3% on Monday. The…
AC Immune Raises $50M, Its Alzheimer’s Targeting Immunotherapy Advances Into Phase 2b Trial
AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer's disease (AD), those individuals